Caroline Gaynor
Principal @ Lightstone Ventures
Dublin, Ireland
Caroline Gaynor is a Series A investor at Lightstone Ventures in Dublin focused on Health Care and Biotechnology. Caroline Gaynor is based out of Dublin, Ireland and is the Chairperson of Irish Venture Capital Association. Caroline Gaynor attended the Trinity College Dublin.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Caroline Gaynor invests in
Stages Caroline Gaynor invests in
Countries Caroline Gaynor invests in
Investment Focus
Industry
- Health Care 2 (40%)
- Biotechnology 2 (40%)
- Biopharma 1 (20%)
- Therapeutics 1 (20%)
- Medical Device 1 (20%)
Stage
- Series A 3 (60%)
- Series B 1 (20%)
Country
- Ireland 1 (20%)
- United States 1 (20%)
- United Kingdom 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ProVerum Medical
|
ProVerum Medical is a healthcare company that develops innovative treatments for benign prostatic hyperplasia (BPH). ProVerum develops the ProVee System, which is a minimally invasive implant that gently opens the blocked part of the urethra without cutting, heating, or removing tissue. | $80M / Series B / Aug 25, 2025 | |
Amber Therapeutics
|
Amber Therapeutics develops the next-generation of bioelectrical therapies that can sense and adapt as well as stimulate, with the potential to radically improve clinical outcomes in patients with functional disorders of the peripheral nervous system. | $101.8M / Series A / Jun 09, 2024 | |
|
ProVerum Medical
|
ProVerum Medical is a healthcare company that develops innovative treatments for benign prostatic hyperplasia (BPH). ProVerum develops the ProVee System, which is a minimally invasive implant that gently opens the blocked part of the urethra without cutting, heating, or removing tissue. | Series A / Jan 11, 2022 | |
|
ProVerum Medical
|
ProVerum Medical is a healthcare company that develops innovative treatments for benign prostatic hyperplasia (BPH). ProVerum develops the ProVee System, which is a minimally invasive implant that gently opens the blocked part of the urethra without cutting, heating, or removing tissue. | $34.1M / Series A / Jan 11, 2022 | |
Catamaran Bio
|
Catamaran Bio is a biotechnology company that specializes in allogeneic immune cell therapies. It offers cell therapy company developing allogeneic, off-the-shelf products for patients with an unmet medical need. It was founded in 2020 and headquartered in Cambridge, Massachusetts. | $42M / Series A / Nov 23, 2020 |
Co-Investors
About Lightstone Ventures
Lightstone Ventures is a global venture capital firm that invests in personalized medicines and targeted therapeutics. Lightstone Ventures was founded in 2012 by the General Partners and other key members of the life science teams of Advanced Technology Ventures (ATV) and Morgenthaler. The firm was formed to capture the upside of investing inbreakthrough life science companies during a time of unique opportunity in space.
Lightstone Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Caroline Gaynor
Principal
|
|||
Christina Isacson
Partner
|
|||
Christopher M. Owens
Founder, President & CEO
|
|||
Christopher M. Owens
Founder, President & CEO
|
|||
Hank Plain
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Caroline Gaynor invest in?
Caroline Gaynor invests primarily in Health Care, Biotechnology and Biopharma startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Caroline Gaynor last invest?
The most recent investment recorded for Caroline Gaynor closed in Aug 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
